Bone as an effect compartment: Models for uptake and release of drugs

Clinical Pharmacokinetics

Volumn 42, Issue 10, 2003, Pages 863-881

  Stepensky, David ^a   Kleinberg, Lilach ^a   Hoffman, Amnon ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM; BISPHOSPHONIC ACID DERIVATIVE; BONE SEEKING AGENT; CEFALOTIN; CEFAZOLIN; CHROMIUM; CLINDAMYCIN; DRUG; FLUORIDE; LATAMOXEF; LEAD; NAFCILLIN; RADIOPHARMACEUTICAL AGENT; RHENIUM; SAMARIUM; TETRACYCLINE; TOBRAMYCIN; UNCLASSIFIED DRUG; VANCOMYCIN;

BINDING AFFINITY; BONE; BONE DISEASE; BONE REMODELING; DRUG DISPOSITION; DRUG HALF LIFE; HUMAN; MORPHOLOGY; NONHUMAN; OSTEOMYELITIS; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW;

BONE AND BONES; BONE RESORPTION; DIAGNOSTIC IMAGING; DIPHOSPHATES; DRUG DELIVERY SYSTEMS; HUMANS; MODELS, BIOLOGICAL; OSTEOBLASTS; OSTEOCLASTS; OSTEOGENESIS;

EID: 0042161657     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200342100-00001     Document Type: Review

References (157)

1. Eriksen EF, Vesterby A, Kassem M, et al. Bone remodeling and bone structure. In: Mundy GR, Martin TJ, editors. Physiology and pharmacology of bone. Heidelberg: Springer-Verlag, 1993
2. Ganong WF. Review of medical physiology. 16th ed. London: Prentice-Hall International Inc., 1993
3. McGowan JA. Bone: target and source of environmental pollutant exposure. Otolaryngol Head Neck Surg 1996; 114 (2): 220-3
4. Silbergeld EK, Sank J, Somerman M, et al. Lead in bone: storage site, exposure source, and target organ. Neurotoxicology 1993; 14 (2-3): 225-36
5. Hoffman A, Stepensky D. Pharmacodynamic aspects of modes of drug administration for optimization of drug therapy. Crit Rev Ther Drug Carrier Syst 1999; 16 (6): 571-639
6. Boxenbaum H. Pharmacokinetics: philosophy of modeling. Drug Metab Rev 1992; 24 (1): 89-120
7. Levy G. Mechanism-based pharmacodynamic modeling. Clin-Pharmacol Ther 1994; 56 (4): 356-8
8. Meibohm B, Derendorf H. Basic concepts of pharmacokinetic/ pharmacodynamic (PK/PD) modelling. Int J Clin Pharmacol Ther 1997; 35 (10): 401-13
9. Gieschke R, Steimer JL. Pharmacometrics: modelling and simulation tools to improve decision making in clinical drug development. Eur J Drug Metab Pharmacokinet 2000; 25 (1): 49-58
10. Mather LE. Anatomical-physiological approaches in pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 2001; 40 (10): 707-22
11. Leggett RW. An age-specific kinetic model of lead metabolism in humans. Environ Health Perspect 1993; 101 (7): 598-616
12. Lin J. Bisphosphonates: a review of their pharmacokinetic properties. Bone 1996; 18 (2): 75-85
13. Hoffman A, Stepensky D, Ezra A, et al. Mode of administration-dependent pharmacokinetics of bisphosphonates and bioavailability determination. Int J Pharm 2001; 220 (1-2): 1-11
14. Monkkonen J, Ylitalo P. The tissue distribution of clodronate (dichloromethylene bisphosphonate) in mice: the effects of vehicle and the route of administration. Eur J Drug Metab Pharmacokinet 1990; 15 (3): 239-43
15. Fujisaki J, Tokunaga Y, Sawamoto T, et al. Osteotropic drug delivery system (ODDS) based on bisphosphonic prodrug: III. pharmacokinetics and targeting characteristics of osteotropic carboxyfluorescein. J Drug Target 1996; 4 (2): 117-23
16. Fujisaki J, Tokunaga Y, Takahashi T, et al. Osteotropic drug delivery system (ODDS) based on bisphosphonic prodrug: V. biological disposition and targeting characteristics of osteotropic estradiol. Biol Pharm Bull 1997; 20 (11): 1183-7
17. Wingen F, Sterz H, Blum H, et al. Synthesis, antitumor activity, distribution and toxicity of 4-[4-[bis(2-chloroethyl)amino]phenyl]-1-hydroxybutane-1 1-bisphosphonic acid (BAD), a new lost derivative with increased accumulation in rat osteosarcoma. J Cancer Res Clin Oncol 1986; 111 (3): 209-19
18. Hirabayashi H. Takahashi T, Fujisaki J, et al. Bone-specific delivery and sustained release of diclofenac, a non-steroidal anti-inflammatory drug, via bisphosphonic prodrug based on the Osteotropic Drug Delivery System (ODDS). J Control Release 2001; 70 (1-2): 183-91
19. Lewington VJ. Targeted radionuclide therapy for bone metastases. Eur J Nucl Med 1993; 20 (1): 66-74
20. Ackery D, Yardley J. Radionuclide-targeted therapy for the management of metastatic bone pain. Semin Oncol 1993; 20 (3 Suppl. 2): 27-31
21. 153Sm-EDTMP in patients with metastatic bone disease. J Nucl Med 2001; 42 (2): 230-6
22. 99mTc-methylene diphosphonate. Semin Nucl Med 2001; 31 (1): 28-49
23. 99mTc-methylene diphosphonate with age: relevance to the pathogenesis of bone loss. J Nucl Med 2000; 41 (9): 1478-83
24. Arend SM, Pauwels EK. Arndt JW, et al. Extraskeletal localization of 99mTc-labeled bone-seeking tracers in bone scintigraphy. Neth J Med 1994; 45 (4): 177-91
25. O'Flaherty EJ. Physiologically based models for bone-seeking elements: IV. kinetics of lead disposition in humans. Toxicol Appl Pharmacol 1993; 118 (1): 16-29
26. O'Flaherty EJ. Physiologically based models for bone-seeking elements: I1. kinetics of lead disposition in rats. Toxicol Appl Pharmacol 1991; 111 (2): 313-31
27. Landrigan PJ. Strategies for epidemiologic studies of lead in bone in occupationally exposed populations. Environ Health Perspect 1991; 91: 81-6
28. Rabinowitz MB. Toxicokinetics of bone lead. Environ Health Perspect 1991; 91: 33-7
29. Kelly R, Buyske D. Metabolism of tetracycline in the rat and in the dog. J Pharm Exp Ther 1960; 130: 144-9
30. Buyske D, Eisner H, Kelly R. Concentration and persistence of tetracycline and chlortetracycline in bone. J Pharm Exper Ther 1960; 130: 150-6
31. Blomquist L, Hanngren A. Whole body autoradiography and fluorography of two tetracycline compounds in tumor-bearing mice. Acta Med Scand 1968; 184: 1-11
32. Ekstrand J, Spak CJ. Fluoride pharmacokinetics: its implications in the fluoride treatment of osteoporosis. J Bone Miner Res 1990; 5 Suppl. 1: s53-61
33. Whitford GM. Intake and metabolism of fluoride. Adv Dent Res 1994; 8 (1): 5-14
34. Turner CH, Boivin G, Meunier PJ. A mathematical model for fluoride uptake by the skeleton. Calcif Tissue Int 1993; 52 (2): 130-8
35. Bonjour J-P, Rizzoli R, Ammann P, et al. Bisphosphonates in clinical medicine. In: Heersche JNM, Kanis JA, editors. Bone and mineral research. Amsterdam: Elsevier, 1994: 205-64
36. Rosen C, Kessenich C. Comparative clinical pharmacology and therapeutic use of bisphosphonates in metabolic bone disease. Drugs 1996; 51 (4): 537-51
37. Rodan GA. Mechanisms of action of bisphosphonates. Annu Rev Pharmacol Toxicol 1998; 38: 375-88
38. van Beek E, Pieterman E, Cohen L, et al. Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem Biophys Res Commun 1999; 264 (1): 108-11
39. Russell RG, Rogers MJ. Bisphosphonates: from the laboratory to the clinic and back again. Bone 1999: 25 (1): 97-106
40. Halasy Nagy JM, Rodan GA, Reszka AA. Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis. Bone 2001; 29 (6): 553-9
41. Lin JH, Lu A. Role of pharmacokinetics and metabolism in drug discovery and development. Pharm Rev 1997; 49 (4): 403-49
42. Fleisch H. Bisphosphonates in bone disease: from the laboratory to the patient. 3rd ed. Berne: The Parthenon Publishing Group, 1997
43. Azuma Y, Sato H, Oue Y, et al. Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models. Bone 1995; 16 (2): 235-45
44. Osterman T, Virtamo T, Kippo K, et al. Distribution of clodronate in the bone of adult rats and its effects on trabecular and cortical bone. J Pharmacol Exp Ther 1997; 280 (2): 1051-6
45. Sato M, Grasser W, Endo N, et al. Bisphosphonate action: alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 1991; 88 (6): 2095-105
46. Lin JH, Chen IW, Duggan DE. Effects of dose, sex, and age on the disposition of alendronate, a potent antiosteolytic bisphosphonate, in rats. Drug Metab Dispos 1992; 20 (4): 473-8
47. 3H-etidronate in rat and mouse bones. Bone 1996; 19 (3): 281-90
48. Ezra A, Hoffman A, Breuer E, et al. A peptide prodrug approach for improving bisphosphonate oral absorption. J Med Chem 2000; 43 (20): 3641-52
49. Pongchaidecha M, Daley Yates FT. Clearance and tissue uptake following 4-hour and 24-hour infusions of pamidronate in rats. Drug Metab Dispos 1993; 21 (1): 100-4
50. Lin JH, Chen IW, Deluna FA. Uptake of alendronate by bone tissue in hypocalcemic and hypercalcemic rats. Drug Metab Dispos 1993; 21 (5): 800-4
51. Lin JH, Chen I-W, Deluna FA. Nonlinear kinetics of alendronate: plasma protein binding and bone uptake. Drug Metab Dispos 1994; 22: 400-5
52. Hoggarth CR, Bennett R, Daley Yates PT. The pharmacokinetics and distribution of pamidronate for a range of doses in the mouse. Calcif Tissue Int 1991; 49 (6): 416-20
53. Canniggia A, Vattimo A. Kinetics of technetium-99m-trimethylene-diphosphonate in normal subjects and pathological conditions: a simple index of bone metabolism. Calcif Tissue Int 1980; 30: 5-13
54. Porras AG, Holland SD, Gertz BJ. Pharmacokinetics of alendronate. Clin Pharmacokinet 1999; 36 (5): 315-28
55. Cremers S, Sparidans R, Den Hartigh J, et al. A pharmacokinetic and pharmacodynamic model for intravenous biphosphonate (pamidronate) in osteoporosis. Eur J Clin Pharmacol 2002; 57: 883-90
56. Van Gelder JM, Golomb G. The evaluation of bisphosphonates as potential drugs for calcium-related disorders. In: Ornoy A, editor. Animal models of human related calcium-metabolic disorders. Boca Raton: CRC Press, 1995: 181-206
57. Stepensky D, Golomb G, Hoffman A. Pharmacokinetic and pharmacodynamic evaluation of intermittent vs continuous alendronate administration in rats. J Pharm Sci 2002; 91 (2): 508-16
58. Hernandez C, Beaupre C, Marcus R, et al. A theoretical analysis of the contributions of remodeling space, mineralization, and bone balance to changes in bone mineral density during alendronate treatment. Bone 2001; 29 Suppl. (3): 511-6
59. Hernandez C, Beaupre C, Marcus R, et al. Long-term predictions of the therapeutic equivalence of daily and less than daily alendronate dosing. J Bone Miner Res 2002; 17 Suppl. (9): 1662 -6
60. Schnitzer T, Bone HG, Crepaldi G, et al. Therapeutic equivalence of alendronate 70mg once-weekly and alendronate 10mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Minano) 2000; 12 (1): 1-12
61. Reid IR, Brown JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002; 346 (9): 653-61
62. Liberman UA, Weiss SR, Broil J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995; 333 (22): 1437-43
63. Ravn P, Neugebauer G, Christiansen C. Association betwen pharmcokinetics of oral ibadronate and clinical response in bone mass and bone turnover in women with postmenopausal osteoporosis. Bone 2002; 30 Suppl. (1): 320-4
64. Wingen F, Pool BL, Klein P, et al. Anticancer activity of bisphosphonic acids in methylnitrosourea-induced mammary carcinoma of the rat-benefit of combining bisphosphonates with cytostatic agents. Invest New Drugs 1988; 6 (3): 155-67
65. Klenner T, Wingen F, Keppler BK, et al. Anticancer-agentlinked phosphonates with antiosteolytic and antineoplastic properties: a promising perspective in the treatment of bonerelated malignancies? J Cancer Res Clin Oncol 1990; 116 (4): 341-50
66. Klenner T, Valenzuela Paz P, Keppler BK, et al. Cisplatin-linked phosphonates in the treatment of the transplantable osteosarcoma in vitro and in vivo. Cancer Treat Rev 1990; 17 (2-3): 253-9
67. Sturtz G, Appere G, Breistol K, et al. A study of the delivery-targeting concept applied to antineoplastic drugs active on human osteosarcoma: I. synthesis and biological activity in nude mice carrying human osteosarcoma xenografts of gembisphosphonic methotrexate analogues. Eur J Med Chem 1992; 27: 825-33
68. Sturtz G, Couthon H, Fabulet O, et al. Synthesis of gembisphosphonic methotrexate conjugates and their biological response towards Walker's osteosarcoma. Eur J Med Chem 1993; 28: 899-903
69. Hosain F, Spencer RP, Couthon HM, et al. Targeted delivery of antineoplastic agent to bone: biodistribution studies of technetium-99m-labeled gem-bisphosphonate conjugate of methotrexate. J Nucl Med 1996; 37 (1): 105-7
70. Fujisaki J, Tokunaga Y, Takahashi T, et al. Osteotropic drug delivery system (ODDS) based on bisphosphonic prodrug: I. synthesis and in vivo characterization of osteotropic carboxyfluorescein. J Drug Target 1995; 3 (4): 273-82
71. Gentili A, Miron SD, Bellon EM. Nonosseous accumulation of bone-seeking radiopharmaceuticals. Radiographics 1990; 10 (5): 871-81
72. King MA, Kilpper RW, Weber DA. A model for local accumulation of bone imaging radiopharmaceuticals. J Nucl Med 1977; 18 (11): 1106-11
73. Lewington VJ, McEwan AJ, Ackery DM, et al. A prospective randomized double blind crossover study to examine the efficacy of strontium-89 in pain pallation in patients with advanced prostate cancer metastatic to bone. Eur J Cancer 1991; 27: 954-8
74. Dahl SG, Allain P, Marie PJ, et al. Incorporation and distribution of strontium in bone. Bone 2001; 28 (4): 446-53
75. Kraeber Bodere F, Campion L, Rousseau C, et al. Treatment of bone metastases of prostate cancer with strontium-89 chloride: efficacy in relation to the degree of bone involvement. Eur J Nucl Med 2000; 27 (10): 1487-93
76. Blake GM, Zivanovic MA, McEwan AJ, et al. Sr-89 therapy: strontium kinetics in disseminated carcinoma of the prostate. Eur J Nucl Med 1986; 12 (9): 447-54
77. Robinson RG, Blake GM, Preston DF, et al. Strontium-89: treatment results and kinetics in patients with painful metastatic prostate and breast cancer in bone. Radiographics 1989; 9 (2): 271-81
78. Laing AH, Ackery DM, Bayly RJ, et al. Strontium-89 chloride for pain pallation in prostatic skeletal malignancy. Br J Radiol 1991; 64: 816-22
79. Cook GJ, Fogelman I. Skeletal metastases from breast cancer: imaging with nuclear medicine. Semin Nucl Med 1999; 29 (1): 69-79
80. 99Tcm-citrate: a new bone imaging radiopharmaceutical. Nucl Med Commun 1999; 20 (11): 1067-76
81. Schwartz Z, Shani J, Soskolne WA, et al. Uptake and biodistribution of technetium-99m-MD32P during rat tibial bone repair. J Nucl Med 1993; 34 (1): 104-8
82. Reske SN. Recent advances in bone marrow scanning, Eur J Nucl Med 1991; 18 (3): 203-21
83. O'Flaherty EJ. PBK modeling for metals: examples with lead, uranium, and chromium. Toxicol Lett 1995; 83: 367-72
84. O'Flaherty EJ. A physiologically based model of chromium kinetics in the rat. Toxicol Appl Pharmacol 1996; 138 (1): 54-64
85. O'Flaherty EJ. Physiologically based models of metal kinetics. Crit Rev Toxicol 1998; 28 (3): 271-317
86. Leggett RW, Eckerman KF. A systemic biokinetic model for polonium. Sci Total Environ 2001; 275 (1-3): 109-25
87. Yokel RA, McNamara P J. Aluminium toxicokinetics: an updated minireview. Pharmacol Toxicol 2001; 88 (4): 159-67
88. Silbergeld EK. Lead in bone: implications for toxicology during pregnancy and lactation. Environ Health Perspect 1991; 91: 63-70
89. Hamilton JD, O'Flaherty EJ. Influence of lead on mineralization during bone growth. Fundam Appl Toxicol 1995; 26 (2): 265 -71
90. O'Flaherty EJ, Inskip MJ, Franklin CA, et al. Evaluation and modification of a physiologically based model of lead kinetics using data from a sequential isotope study in cynomolgus monkeys. Toxicol Appl Pharmacol 1998; 149 (1): 1-16
91. Pounds JG, Leggett RW. The ICRP age-specific biokinetic model for lead: validations, empirical comparisons, and explorations. Environ Health Perspect 1998; 106 Suppl. 6: 1505-11
92. US Environmental Protection Agency. Guidance manual for the integrated exposure uptake biokinetic model for lead in children. EPA/540/R-93/081.PB93-963510. Washington: US Environmental Protection Agency, 1994
93. Mason HJ. A biokinetic model for lead metabolism with a view to its extension to pregnancy and lactation: (1) further validation of the original model for non-pregnant adults. Sci Total Environ 2000; 246 (1): 69-78
94. O'Flaherty EJ. Physiologically based models for bone-seeking elements: V. lead absorption and disposition in childhood. Toxicol Appl Pharmacol 1995; 131 (2): 297-308
95. Fleming DE, Chettle DR, Webber CE, et al. The O'Flaherty model of lead kinetics: an evaluation using data from a lead smelter population. Toxicol Appl Pharmacol 1999; 161 (1): 100-9
96. Beck BD, Mattuck RL, Bowers TS, et al. The development of a stochastic physiologically-based pharmacokinetic model for lead. Sci Total Environ 2001; 274 (1-3): 15-9
97. Carek PJ, Dickerson LM, Sack JL. Diagnosis and management of osteomyelitis. Am Fam Physician 2001; 63 (12): 2413-20
98. Mader J, Calhoun J. Osteomyelitis. In: Mandell G, Bennet J, Dolin R, editors. Douglas and Bennett's principles and practice of infectious diseases. Philadelphia: Churchill Livingstone, 2000: 1182-96
99. Lew DP, Waldvogel FA. Osteomyelitis. N Engl J Med 1997; 336 (14): 999-1007
100. Henry SL, Galloway KP. Local antibacterial therapy for the management of orthopaedic infections: pharmacokinetic considerations. Clin Pharmacokinet 1995; 29 (1): 36-45
101. Mader JT, Shirtliff ME, Bergquist SC, et al. Ant[microbial treatment of chronic osteomyelitis. Clin Orthop 1999; 360: 47-65
102. Mader J, Adams K. Experimental osteomyelitis. In: Schlossberg D, editor. Orthopedic infection. New York: Springer-Verlag, 1988: 39-48
103. Mader JT, Adams K, Morrison L. Comparative evaluation of cefazolin and clindamycin in the treatment of experimental Staphylococcus aureus osteomyelitis in rabbits. Antimicrob Agents Chemother 1989; 33 (10): 1760-4
104. Bloom JD, Fitzgerald RH, Washington II JA, et al The transcapillary passage and interstitial fluid concentration of penicillin in canine bone. J Bone Joint Surg Am 1980; 62 (7): 1168-75
105. Lunke RJ, Fitzgerald RH, Washington II JA. Pharmacokinetics of cefamandole in osseous tissue. Antimicrob Agents Chemother 1981; 19 (5): 851-8
106. Daly RC, Fitzgerald RH, Washington II JA. Penetration of cefazolin into normal and osteomyelitic canine cortical bone. Antimicrob Agents Chemother 1982; 22 (3): 461-9
107. Fitzgerald R. Antibiotic distribution in normal and osteomyelitic bone. Orthop Clin North Am 1984: 15: 537-46
108. Fitzgerald R, Whalen J, Peterson S. Pathophysiology of osteomyelitis and pharmacokinetics of ant[microbial agents in normal and osteomyelitic bone. In: Esterhai JL, Gristina AG, Poss R, et al. editors. Musculoskeletal infection. Park Ridge: American Academy of Orthopedic Surgeons, 1990: 387-99
109. Raasch R. Osteomyelitis/septic arthritis. In: Young L, Koda-Kimble M, editors. Applied therapeutics: the clinical use of drugs. Vancouver (WA): Applied Therapeutics Inc, 1995: 1-12
110. Dash AK, Suryanarayanan R. An implantable dosage form for the treatment of bone infections. Pharm Res 1992; 9 (8): 993-1002
111. Overbeck JP, Winckler ST, Meffert R, et al. Penetration of ciprofloxacin into bone: a new bioabsorbable implant. J Invest Surg 1995; 8 (3): 155-62
112. Zhang X, Wyss UP, Pichora D, et al. Biodegradable controlled antibiotic release devices for osteomyelitis: optimization of release properties. J Pharm Pharmacol 1994: 46 (9): 718-24
113. Jain AK, Panchagnula R. Skeletal drug delivery systems. Int J Pharm 2000; 206 (1-2): 1-12
114. Kanellakopoulou K, Giamarellos Bourboulis EJ. Carrier systems for the local delivery of antibiotics in bone infections. Drugs 2000; 59 (6): 1223-32
115. Kanis JA, McCloskey EV. Bone turnover and biochemical markers in malignancy. Cancer 1997; 80 (8 Suppl.): 1538-45
116. Hu H, Rabinowitz M, Smith D. Bone lead as a biological marker in epidemiologic studies of chronic toxicity: conceptual paradigms. Environ Health Perspect 1998; 106 (1): 1-8
117. Delmas PD, Eastell R, Gamero P, et al. The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporos Int 2000; 11 Suppl. 6:s2-17
118. Delmas PD. Markers of bone turnover for monitoring treatment of osteoporosis with antiresorptive drugs. Osteoporos Int 2000; 11 Suppl. 6: s66-76
119. Woitge H, Siebel M. Biochemical markers to survey bone resorption. Rheum Dis Clin North Am 2001; 27: 49-80
120. 3H-tetracycline. Calcif Tissue Res 1976; 20 (3): 275-90
121. 3H-tetracycline loss as a measure of bone resorption in maturing rats. Calcif Tissue Int 1997; 61 (5): 412-7
122. Klein L. Direct measurement of hone resorption and calcium conservation during vitamin D deficiency or hypervitaminosis D. Proc Natl Acad Sci U S A 1980; 77 (4): 1818-22
123. 3H]collagen from whole bones of growing rats. J Orthop Res 1983; 1 (1): 50-6
124. Muhlbauer R, Fleisch H. A method for continual monitoring of bone resorption in rats: evidence for a diurnal rhythm. Am J Physiol 1990; 259: 679-89
125. 3H]-tetracycline excretion, is mediated by parathyroid hormone. Bone 1995; 17 Suppl. 4: 449S-53S
126. Svanberg M, Mattila P, Knuuttila M. Dietary xylitol retards the ovaryectomy-induced increase of bone turnover in rats. Calcif Tissue Int 1997; 60: 462-6
127. 3H-tetracycline from rat bone in vitro. Calcif Tissue Res 1976; 2: 229-34
128. 3H]tetracycline. J Pharm Sci 1989; 78 (10): 823-8
129. Klein L, Li QX, Donovan CA, et al. Variation of resorption rates in vivo of various bones in immature rats. Bone Miner 1990; 8 (2): 169-75
130. Muhlbauer RC, Bauss F, Schenk R, et al. BM 21.0955, a potent new bisphosphonate to inhibit bone resorption. J Bone Miner Res 1991; 6 (9): 1003-11
131. 3H]tetracycline kinetics and indices of kidney function facilitate study of the activity and toxic effects of bisphosphonates in bone resorption. Pharm Res 1992: 9 (8): 1018-23
132. Antic V, Fleisch H, Muhlbauer R. Effect of bisphosphonates on the increase in bone resorption induced by a low calcium diet. Calcif Tissue Int 1996; 58: 443-8
133. Cecchini M, Fleisch H, Muhlbauer R. Ipriflavone inhibits bone resorption in intact and ovariectomized rats. Calcif Tissue Int 1997; 61 Suppl. 1: S9-11
134. Milch R, Rail D, Tobie J. Fluorescence of tetracycline antibiotics in bone. J Bone Joint Surg 1958; 40: 897-910
135. Frost HM. Tetracyclines and fetal bones. Henry Ford Hosp Med J 1965; 13 (4): 403-10
136. Stewart D. The reincorporation in calcified tissues of tetracycline released following its deposition in the bone of rats. Arch Oral Biol 1973; 18: 759-64
137. 14C-collagen from bone of prelabeled rats. Bone 1986; 7: 392-3
138. 3H-tetracycline. Calcif Tissue Res 1978; 25 (3): 255-63
139. Klein L. Wong KM, Simrnelink JW. Biochemical and autoradiographic evaluation of bone turnover in prelabeled dogs and rabbits on normal and calcium-deficient diets. Bone 1985; 6 (5): 395-9
140. Chulski T, Johnson R, Schlagel C. Direct proportionality of urinary excretion rate and serum level of tetracycline in human subjects. Nature 1963; 198: 450-3
141. Rao HV, Beliles RP, Whitford GM, et al. A physiologically based pharmacokinetic model for fluoride uptake by bone. Regul Toxicol Pharmacol 1995; 22 (1): 30-42
142. Whitford GM. Fluoride metabolism and excretion in children. J Public Health Dent 1999; 59 (4): 224-8
143. Eble DM, Deaton TG, Wilson FC, et al. Fluoride concentrations in human and rat bone. J Public Health Dent 1992; 52 (5): 288-91
144. Friedman M, Steinberg D. Sustained-release delivery systems for treatment of dental diseases. Pharm Res 1990; 7 (4): 313-7
145. Anonymous. Position of the American Dietetic Association: the impact of fluoride on health. J Am Diet Assoc 2001; 101 (1): 126-32
146. Caverzasio J, Palmer G, Bonjour JP. Fluoride: mode of action. Bone 1998; 22 (6): 585-9
147. Riggs BL, O'Fallon WM, Lane A, et al. Clinical trial of fluoride therapy in postmenopausal osteoporotic women: extended observations and additional analysis. J Bone Miner Res 1994; 9 (2): 265-75
148. Meunier PJ, Sebert JL, Reginster JY, et al. Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: the FAVO Study. Osteoporos Int 1998; 8 (1): 4-12
149. Laufer D, Ben Shachar D, Livne E, et al. Enhancing effects of fluoride-containing ceramic implants on bone formation in the dog femur. J Craniomaxillofac Surg 1988; 16 (1): 40-5
150. Anderson PA, Copenhaver JC, Tencer AF, et al. Response of cortical bone to local controlled release of sodium fluoride: the effect of implant insertion site. J Orthop Res 1991; 9 (6): 890-901
151. Guise JM, McCormack A, Anderson PA, et al. Effect of controlled local release of sodium fluoride on trabecular bone. J Orthop Res 1992; 10 (4): 588-95
152. Magnan B, Gabbi C, Regis D. Sodium fluoride sustained-release bone cement: an experimental study in vitro and in vivo. Acta Orthop Belg 1994; 60 (1): 72-9
153. Allolio B, Lehmann R. Drinking water fluoridation and bone. Exp Clin Endocrinol Diabetes 1999; 107 (1): 12-20
154. Castioni MV, Baehni PC, Gurny R. Current status in oral fluoride pharmacokinetics and implications for the prophylaxis against dental caries. Eur J Pharm Biopharm 1998; 45: 101-11
155. Ekstrand J, Alvan G, Boreus LO, et al. Pharmacokinetics of fluoride in man after single and multiple oral doses. Eur J Clin Pharmacol 1977; 12 (4): 311-7
156. 18F]fluoride kinetics in humans. J Nucl Med 1978; 19 (12): 1301-9
157. 18F]fluoride kinetics in rats. J Nucl Med 1979; 20 (11): 1150-7